19.4(top 1%)
Impact Factor
20.7(top 1%)
extended IF
178(top 1%)
H-Index
1K
authors
2.1K
papers
114.8K
citations
5.6K
citing journals
86K
citing authors

Most Cited Articles of Nature Reviews Clinical Oncology

TitleYearCitations
Delivering nanomedicine to solid tumors20102.3K
Tumour-associated macrophages as treatment targets in oncology20171.6K
Radiomics: the bridge between medical imaging and personalized medicine20171.6K
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease20161.2K
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications20171.2K
Liquid biopsy: monitoring cancer-genetics in the blood20131.1K
Tumour heterogeneity and resistance to cancer therapies20181.1K
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities20181.1K
MicroRNAs in body fluids--the mix of hormones and biomarkers20111.1K
Targeting the IL-6/JAK/STAT3 signalling axis in cancer2018975
Integrating liquid biopsies into the management of cancer2017970
The immune contexture in cancer prognosis and treatment2017935
Patient-derived tumour xenografts as models for oncology drug development2012900
Image-guided cancer surgery using near-infrared fluorescence2013848
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update2015789
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways2011757
Clinical relevance of circulating cell-free microRNAs in cancer2014740
Molecular therapies and precision medicine for hepatocellular carcinoma2018735
Cancer metabolism: a therapeutic perspective2017659
Targeted agents and immunotherapies: optimizing outcomes in melanoma2017654
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy2016640
Extracellular vesicles in cancer - implications for future improvements in cancer care2018638
Cancer-related fatigue--mechanisms, risk factors, and treatments2014629
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges2018627
Development of PI3K inhibitors: lessons learned from early clinical trials2013607